Form 4: Y-mAbs Therapeutics Director Acquires New Equity, Adjusts Holdings

A director and 10% owner of Y-mAbs Therapeutics, Inc. reported the acquisition of restricted stock units and employee stock options, alongside a disposal of common stock, as part of compensation.

Summary

• Johan Wedell-Wedellsborg, a Director and 10% Owner of Y-mAbs Therapeutics, Inc. (YMAB), reported changes in beneficial ownership.
• Acquired 25,080 Restricted Stock Units (RSUs) at a price of $0 per share.
• Disposed of 30,905 shares of Common Stock at a price of $0 per share.
• Acquired 33,450 Employee Stock Options at a price of $0, with an exercise price of $4.51 per share.
• Following these transactions, direct beneficial ownership of Common Stock is 30,905 shares.
• Indirect beneficial ownership of Common Stock remains 4,559,233 shares through WG Biotech ApS, where the reporting person is the majority owner with sole voting and dispositive power.
• Direct beneficial ownership of Employee Stock Options is 33,450 options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the acquisition of new equity awards (RSUs and stock options) by a director and significant owner, which generally indicates alignment of interests with the company's future performance. The disposal of shares at $0 is likely a non-market transaction (e.g., tax withholding) and does not necessarily reflect a negative outlook.

Positives

• The acquisition of 25,080 Restricted Stock Units (RSUs) and 33,450 Employee Stock Options aligns the director's interests with those of shareholders, as these awards typically vest based on continued service or performance.
• The RSUs and stock options were granted under the Issuer's 2018 Equity Incentive Plan, indicating a structured compensation approach for key personnel.

Negatives

• The disposal of 30,905 shares of Common Stock at a $0 price is unusual for a market transaction and typically indicates shares withheld for tax obligations upon the vesting of other equity awards, rather than a direct sale for cash.

Future Outlook

The acquired Restricted Stock Units (RSUs) are set to vest in full on the earlier of the first anniversary of the grant date or the date immediately preceding the Issuer's annual meeting of stockholders in 2026, contingent on continued service. The employee stock options will vest in equal monthly installments until the first anniversary of the grant date, subject to continued service, and are exercisable immediately upon vesting.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, which is a common practice across publicly traded companies in the biotechnology and pharmaceutical sectors. Such filings provide transparency into how company leadership's financial interests are aligned with shareholder value.

Related Party Transactions

• The reporting person's indirect beneficial ownership of 4,559,233 shares of Common Stock is held through WG Biotech ApS, where the reporting person is the majority owner and holds sole voting and dispositive power.

Stakeholder Impact

• Shareholders may view the acquisition of new equity awards by a director as a positive sign of management's commitment and alignment with long-term company performance.
• The compensation structure, including RSUs and stock options, directly impacts the financial incentives for key personnel.

Next Steps

• Continued vesting of 25,080 Restricted Stock Units (RSUs) until the earlier of the first anniversary of the grant date or the date immediately preceding the Issuer's annual meeting of stockholders in 2026.
• Continued vesting of 33,450 Employee Stock Options in equal monthly installments until the first anniversary of the grant date.

Key Dates

Keywords

Y-mAbs Therapeutics, YMAB, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Employee Stock Options, Director, 10% Owner, Equity Incentive Plan